DV
Dividend Vision

PRPO — Precipio Inc

Precipio Inc (PRPO)

Total return is -100.0% over the past 26.1 years, 823.3 points behind SPY at 723.3%. Its deepest 1-year drawdown was 34.5%.

Precipio is a healthcare biotechnology company that develops cancer diagnostic products and services, including HemeScreen genetic diagnostic panels for blood cancer testing and IV-Cell proprietary cell culture media for hematopoietic cell research. The company does not currently distribute dividends to shareholders. Precipio appeals primarily to investors seeking exposure to the diagnostic oncology sector rather than those focused on generating current income.

PRPO key facts

Asset type
Stock
Asset class
Equity
Inception date
07/18/2000
Last close
$23.50
Market cap
$41,824,504
Average volume
75800.0
Payment date
04/29/2019
Beta
1.277
Payout ratio
0.0
Forward P/E
15.4321
EPS
$-0.43